Dr. Raya Saba, MD

Dr. Saba practices at Mercy Hospital St. Louis in Saint Louis, Missouri, part of Mercy.

Dr. Saba's NPI, 1902154743, was assigned on August 28, 2012. Dr. Saba holds Missouri license 2016015284.

Dr. Saba's primary practice is Mercy Hospital St. Louis, at 615 New Ballas Road, Saint Louis, MO 63141 in St. Louis County. The practice phone is (314) 251-6000.

Dr. Saba's primary practice is Mercy Hospital St. Louis in Saint Louis, Missouri, part of Mercy. Dr. Saba is also affiliated with Mercy Hospital South. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Saba to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Saba practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Saba's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Saba is licensed in Missouri.

CMS data shows 355 Medicare services from Dr. Saba across 5 procedure codes in 2024, for 171 Medicare patients. Medicare paid $30,096 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 171 Medicare patients who saw Dr. Saba in 2024. The largest group is 65 to 74, with 69 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Saba's median patient age at 71, with 56% women.

In 2024, Dr. Saba wrote 434 Medicare Part D claims for 80 patients. 61% of them were for generic drugs. CMS names the drug for 276 of them, across 12 drugs with 11 or more claims each, at $1,445,911 in total drug cost. In 2019, CMS named 26 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Saba for performance year 2024, reported as part of a group. Dr. Saba accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 30 papers to Dr. Saba, published from 2013 to 2023. 2013 was the busiest year, with 12. The most frequent topics are Tomography, X-Ray Computed, Antineoplastic Combined Chemotherapy Protocols and Brentuximab Vedotin. Dr. Saba has published most often in BMJ Case Rep. Dr. Saba's most frequent co-authors are Aibek Mirrakhimov, MD, Alaa Ali, MD and Alan D. Gilman, MD.

Dmand AI links Dr. Saba to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Lymphoma, T-Cell and Lymphoma, Non-Hodgkin.

CMS Open Payments shows 38 general payments to Dr. Saba from 29 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. AstraZeneca Pharmaceuticals LP paid the most, $2,388.